Health Care [ 6/12 ] | Biotechnology [ 26/74 ]
NASDAQ | Common Stock
Lyell Immunopharma, Inc., a clinical-stage cell therapy company, develops chimeric antigen receptor (CAR) T-cell product candidates for patients with hematologic malignancies and solid tumors.
The company develops therapies using various approaches, such as c-Jun overexpression and NR4A3 gene knockout, to endow functional resistance to exhaustion; Epi-R to generate population of stem-like T cells with reduced exhaustion and improved proliferation and antitumor activity; CD62L positive enrichment to generate CAR T cells with enhanced antitumor activity; and Stim-R, a proprietary synthetic-cell mimetic.
It is also developing IMPT-314, a dual-targeting CD19/CD20 CAR T-cell product candidate that is in Phase 1/2 clinical development for the treatment of patients with aggressive relapsed/refractory large B-cell non-Hodgkin lymphoma; and solid tumors program which is in preclinical trial targeting solid tumor indications.
Lyell Immunopharma, Inc. was incorporated in 2018 and is headquartered in South San Francisco, California.
| Reported date | EPSChange YoY | EstimateSurprise |
|---|---|---|
| Mar 12, 25 | -0.17 Increased by +13.95% | -0.13 Decreased by -32.38% |
| Nov 8, 24 | -0.17 Increased by 0.00% | -0.20 Increased by +15.00% |
| Aug 8, 24 | -0.18 Increased by 0.00% | -0.20 Increased by +12.20% |
| May 7, 24 | -0.15 Increased by +34.78% | -0.21 Increased by +28.57% |
| Feb 28, 24 | -0.20 Decreased by -400.00% | -0.23 Increased by +13.04% |
| Nov 7, 23 | -0.17 Increased by +39.29% | -0.25 Increased by +32.00% |
| Aug 8, 23 | -0.18 Decreased by -20.00% | -0.27 Increased by +33.33% |
| May 4, 23 | -0.23 Increased by +17.86% | -0.28 Increased by +17.86% |
| Fiscal ending date | RevenueChange YoY | IncomeChange YoY | ProfitChange YoY |
|---|---|---|---|
| Dec 31, 24 | 11.00 K Decreased by -15.38% | -191.94 M Decreased by -262.62% | Decreased by -1.74 M% Decreased by -328.55% |
| Sep 30, 24 | 34.00 K Increased by +36.00% | -44.58 M Increased by +12.33% | Decreased by -131.13 K% Increased by +35.54% |
| Jun 30, 24 | 13.00 K Decreased by -51.85% | -45.81 M Increased by +28.30% | Decreased by -352.38 K% Decreased by -48.91% |
| Mar 31, 24 | 3.00 K Decreased by -95.38% | -60.67 M Increased by +54.26% | Decreased by -2.02 M% Decreased by -891.07% |
| Dec 31, 23 | 13.00 K Decreased by -73.13% | -52.93 M Decreased by -2.27 K% | Decreased by -407.15 K% Decreased by -8.18 K% |
| Sep 30, 23 | 25.00 K Increased by +733.33% | -50.85 M Increased by +31.35% | Decreased by -203.41 K% Increased by +91.76% |
| Jun 30, 23 | 27.00 K Decreased by -99.92% | -63.89 M Decreased by -75.89% | Decreased by -236.63 K% Decreased by -232.74 K% |
| Mar 31, 23 | 65.00 K Decreased by -88.25% | -132.63 M Decreased by -95.87% | Decreased by -204.05 K% Decreased by -1.57 K% |